Cyclo Therapeutics, Inc.
News
Cyclo Therapeutics Presents Encouraging Preliminary Safety Data from Ongoing Pivotal Phase 3 Study and Substudy for the Treatment of Niemann-Pick Disease Type C1 (NPC1)
Business Wire Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (Cyclo Therapeutics or the Company), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for...\n more…
Ascendiant Capital Markets Lowers Cyclo Therapeutics (NASDAQ:CYTH) Price Target to $0.95
Zolmax Cyclo Therapeutics (NASDAQ:CYTH - Get Free Report) had its price objective reduced by investment analysts at Ascendiant Capital Markets from $2.60 to $0.95 in a research report issued on Monday...\n more…
Cyclo Therapeutics (NASDAQ:CYTH) Given Hold Rating at Maxim Group
Ticker Report Maxim Group reiterated their hold rating on shares of Cyclo Therapeutics (NASDAQ:CYTH - Free Report) in a research report sent to investors on Tuesday morning, Benzinga reports. A number of other...\n more…
Head-To-Head Survey: Cyclo Therapeutics (NASDAQ:CYTH) & HilleVax (NASDAQ:HLVX)
Ticker Report HilleVax (NASDAQ:HLVX - Get Free Report) and Cyclo Therapeutics (NASDAQ:CYTH - Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two...\n more…
Cyclo Therapeutics (NASDAQ:CYTH) PT Lowered to $0.95 at Ascendiant Capital Markets
Ticker Report Cyclo Therapeutics (NASDAQ:CYTH - Free Report) had its price objective reduced by Ascendiant Capital Markets from $2.60 to $0.95 in a report issued on Monday, Benzinga reports. They currently have a...\n more…